Clopidogrel vs. Aspirin for Cardiovascular Risk Reduction in Patients With Staphylococcus Aureus Bacteremia

What this Trial Is About

Researchers are evaluating the effects of clopidogrel compared to aspirin in patients with Staphylococcus aureus bloodstream infections who are already taking aspirin for secondary prevention of cardiovascular events. This open-label randomized controlled trial aims to determine if switching from aspirin to clopidogrel, which may have activity against S. aureus, can improve patient outcomes. The study is a sub-study of the larger Staphylococcus aureus Network Adaptive Platform (SNAP) trial and could lead to a future Phase 3 trial for broader populations. Participants will be randomly assigned to either stop aspirin and start clopidogrel without a loading dose or continue their current aspirin treatment. The trial is designed to compare these two approaches for cardiovascular risk reduction in the context of S. aureus infection. The treatment period coincides with enrollment in the SNAP trial, and patients are monitored throughout. During the study, researchers will assess outcomes at 90 days after enrollment in the SNAP trial, focusing on a ranking system called the Desirability of Outcome Ranking (DOOR). Additional measures include clinical failure, adverse events leading to treatment changes, mortality, infectious complications, bleeding events, thromboembolic events, strokes, heart attacks, and other arterial events. Participation involves regular monitoring and data collection as part of the SNAP trial protocol up to the study end date in January 2030.

Clopidogrel vs. Aspirin for Cardiovascular Risk Reduction in Patients With S. Aureus Bacteremia